Glucose-Dependent Insulinotropic Polypeptide Stimulates Osteopontin Expression in the Vasculature via Endothelin-1 and CREB

Glucose-dependent insulinotropic polypeptide (GIP) is an incretin hormone with extrapancreatic effects beyond glycemic control. Here we demonstrate unexpected effects of GIP signaling in the vasculature. GIP induces the expression of the proatherogenic cytokine osteopontin (OPN) in mouse arteries via local release of endothelin-1 and activation of CREB. Infusion of GIP increases plasma OPN concentrations in healthy individuals. Plasma endothelin-1 and OPN concentrations are positively correlated in patients with critical limb ischemia. Fasting GIP concentrations are higher in individuals with a history of cardiovascular disease (myocardial infarction, stroke) when compared with control subjects. GIP receptor (GIPR) and OPN mRNA levels are higher in carotid endarterectomies from patients with symptoms (stroke, transient ischemic attacks, amaurosis fugax) than in asymptomatic patients, and expression associates with parameters that are characteristic of unstable and inflammatory plaques (increased lipid accumulation, macrophage infiltration, and reduced smooth muscle cell content). While GIPR expression is predominantly endothelial in healthy arteries from humans, mice, rats, and pigs, remarkable upregulation is observed in endothelial and smooth muscle cells upon culture conditions, yielding a “vascular disease–like” phenotype. Moreover, the common variant rs10423928 in the GIPR gene is associated with increased risk of stroke in patients with type 2 diabetes.

[1]  K. Narayan,et al.  Clinical risk factors, DNA variants, and the development of type 2 diabetes. , 2009, The New England journal of medicine.

[2]  G. Berglund,et al.  Elevated Lp-PLA2 Levels Add Prognostic Information to the Metabolic Syndrome on Incidence of Cardiovascular Events Among Middle-Aged Nondiabetic Subjects , 2007, Arteriosclerosis, thrombosis, and vascular biology.

[3]  J. Mehta,et al.  Glucagon-like Peptide-1 Receptor Agonist Liraglutide Inhibits Endothelin-1 in Endothelial Cell by Repressing Nuclear Factor-Kappa B Activation , 2013, Cardiovascular Drugs and Therapy.

[4]  M. Nauck,et al.  Is the Diminished Incretin Effect in Type 2 Diabetes Just an Epi-Phenomenon of Impaired β-Cell Function? , 2010, Diabetes.

[5]  L. Glimcher,et al.  The transcription factor NFAT4 is involved in the generation and survival of T cells. , 1998, Immunity.

[6]  Thomas W. Mühleisen,et al.  Large-scale association analysis identifies 13 new susceptibility loci for coronary artery disease , 2011, Nature Genetics.

[7]  I. Gonçalves,et al.  Changes Related to Age and Cerebrovascular Symptoms in the Extracellular Matrix of Human Carotid Plaques , 2003, Stroke.

[8]  I. Gonçalves,et al.  Evidence for altered inflammatory and repair responses in symptomatic carotid plaques from elderly patients. , 2014, Atherosclerosis.

[9]  Kazutomo Inoue,et al.  Effects of gastric inhibitory polypeptide and glucagon on portal venous and hepatic arterial flow in conscious dogs , 1992, Digestive Diseases and Sciences.

[10]  Xiaoping Zhou,et al.  3,5-Bis(trifluoromethyl)pyrazoles: a novel class of NFAT transcription factor regulator. , 2000, Journal of medicinal chemistry.

[11]  M. Klapholz,et al.  Osteopontin in Cardiovascular Disease: A Potential Therapeutic Target , 2010, Cardiology in review.

[12]  M. Renault,et al.  CREB Mediates UTP-Directed Arterial Smooth Muscle Cell Migration and Expression of the Chemotactic Protein Osteopontin via Its Interaction with Activator Protein-1 Sites , 2007, Circulation research.

[13]  M. Murakami,et al.  Development of atherosclerosis in osteopontin transgenic mice , 2002, Heart and Vessels.

[14]  P. Doevendans,et al.  Local Atherosclerotic Plaques Are a Source of Prognostic Biomarkers for Adverse Cardiovascular Events , 2010, Arteriosclerosis, thrombosis, and vascular biology.

[15]  P. Little,et al.  Endothelin-1 signalling in vascular smooth muscle: pathways controlling cellular functions associated with atherosclerosis. , 2008, Atherosclerosis.

[16]  T. Hirano,et al.  Glucose-Dependent Insulinotropic Polypeptide Prevents the Progression of Macrophage-Driven Atherosclerosis in Diabetic Apolipoprotein E-Null Mice , 2012, PloS one.

[17]  Hyun Joon Kim,et al.  Upregulation of glucose-dependent insulinotropic polypeptide and its receptor in the retina of streptozotocin-induced diabetic rats , 2002, Current eye research.

[18]  P. Hellstrand.  Long-term effects of intracellular calcium and growth factors on excitation and contraction in smooth muscle. , 1998, Acta physiologica Scandinavica.

[19]  Deepak L. Bhatt,et al.  Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. , 2013, The New England journal of medicine.

[20]  J. Holst,et al.  Degradation of endogenous and exogenous gastric inhibitory polypeptide in healthy and in type 2 diabetic subjects as revealed using a new assay for the intact peptide. , 2000, The Journal of clinical endocrinology and metabolism.

[21]  M. Panhwar,et al.  A Naturally Occurring GIP Receptor Variant Undergoes Enhanced Agonist-Induced Desensitization, Which Impairs GIP Control of Adipose Insulin Sensitivity , 2014, Molecular and Cellular Biology.

[22]  J. Golledge,et al.  Osteoprotegerin and Osteopontin Are Expressed at High Concentrations Within Symptomatic Carotid Atherosclerosis , 2004, Stroke.

[23]  A. Gottsäter,et al.  Cardiac Function, Inflammatory Mediators and Mortality in Critical Limb Ischemia , 2006, Angiology.

[24]  C. Rotella,et al.  Cardio Vascular Diabetology Open Access Original Investigation , 2022 .

[25]  C. Forsblom,et al.  Diabetic nephropathy is associated with low-grade inflammation in Type 1 diabetic patients , 2003, Diabetologia.

[26]  Harumi Uto-Kondo,et al.  Dipeptidyl Peptidase‐4 Inhibitors Attenuate Endothelial Function as Evaluated by Flow‐Mediated Vasodilatation in Type 2 Diabetic Patients , 2013, Journal of the American Heart Association.

[27]  E. Agardh,et al.  Nuclear Factor of Activated T‐cells (NFAT) regulates osteopontin expression in arterial smooth muscle in response to diabetes‐induced hyperglycemia , 2010 .

[28]  L. Groop,et al.  Pleiotropic Effects of GIP on Islet Function Involve Osteopontin , 2011, Diabetes.

[29]  Chunxiang Zhang,et al.  The early- and late stages in phenotypic modulation of vascular smooth muscle cells: differential roles for lysophosphatidic acid. , 2008, Biochimica et biophysica acta.

[30]  G. Berglund,et al.  The Malmo Diet and Cancer Study. Design and feasibility. , 1993, Journal of internal medicine.

[31]  Julie A. Wilkins,et al.  Potent Inhibition of NFAT Activation and T Cell Cytokine Production by Novel Low Molecular Weight Pyrazole Compounds* , 2001, The Journal of Biological Chemistry.

[32]  R. Pederson,et al.  A novel pathway for regulation of glucose‐dependent insulinotropic polypeptide receptor expression in β‐cells , 2003, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[33]  G. Berglund,et al.  Blood Pressure in Relation to the Incidence of Cerebral Infarction and Intracerebral Hemorrhage: Hypertensive Hemorrhage: Debated Nomenclature Is Still Relevant , 2007, Stroke.

[34]  M. Pencina,et al.  Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes. , 2015, The New England journal of medicine.

[35]  C. Isales,et al.  Glucose-dependent insulinotropic peptide stimulates thymidine incorporation in endothelial cells: role of endothelin-1. , 2003, American journal of physiology. Endocrinology and metabolism.

[36]  N. Sattar,et al.  Lessons from SAVOR and EXAMINE: some important answers, but many open questions. , 2014, Journal of diabetes and its complications.

[37]  G. Owens,et al.  Molecular regulation of vascular smooth muscle cell differentiation in development and disease. , 2004, Physiological reviews.

[38]  O. Wiklund,et al.  Fatty acids modulate the effect of darglitazone on macrophage CD36 expression , 2003, European journal of clinical investigation.

[39]  L. Norgren,et al.  Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). , 2007, Journal of vascular surgery.

[40]  Donghong Ju,et al.  Disruption of actin cytoskeleton mediates loss of tensile stress induced early phenotypic modulation of vascular smooth muscle cells in organ culture. , 2010, Experimental and molecular pathology.

[41]  T. Shigematsu,et al.  Enhanced expression of osteopontin in human diabetic artery and analysis of its functional role in accelerated atherogenesis. , 2000, Arteriosclerosis, thrombosis, and vascular biology.

[42]  E. Agardh,et al.  Vascular Cellular Adhesion Molecule-1 (VCAM-1) Expression in Mice Retinal Vessels Is Affected by Both Hyperglycemia and Hyperlipidemia , 2010, PloS one.

[43]  S. Bonner-Weir,et al.  Downregulation of GLP-1 and GIP Receptor Expression by Hyperglycemia , 2007, Diabetes.

[44]  A. Lochner,et al.  The many faces of H89: a review. , 2006, Cardiovascular drug reviews.

[45]  Santiago Lamas,et al.  Functional Cooperation Between Smad Proteins and Activator Protein-1 Regulates Transforming Growth Factor-&bgr;–Mediated Induction of Endothelin-1 Expression , 2003, Circulation research.

[46]  L. Groop,et al.  Classifying diabetes according to the new WHO clinical stages , 2004, European Journal of Epidemiology.

[47]  J. Molkentin,et al.  High Glucose Activates Nuclear Factor of Activated T Cells in Native Vascular Smooth Muscle , 2006, Arteriosclerosis, thrombosis, and vascular biology.

[48]  A. Miyazaki,et al.  Native incretins prevent the development of atherosclerotic lesions in apolipoprotein E knockout mice , 2011, Diabetologia.

[49]  F. Rubino,et al.  Gastric Inhibitory Peptide Controls Adipose Insulin Sensitivity via Activation of cAMP-response Element-binding Protein and p110β Isoform of Phosphatidylinositol 3-Kinase* , 2011, The Journal of Biological Chemistry.

[50]  K. Hirokawa,et al.  Osteopontin mRNA is expressed by smooth muscle-derived foam cells in human atherosclerotic lesions of the aorta. , 1993, The Journal of clinical investigation.

[51]  Jian Xu,et al.  Calcineurin/NFAT Coupling Participates in Pathological, but not Physiological, Cardiac Hypertrophy , 2004, Circulation research.

[52]  Reiko Ohmori,et al.  High plasma levels of osteopontin in patients with restenosis after percutaneous coronary intervention. , 2006, Arteriosclerosis, thrombosis, and vascular biology.

[53]  Harald Sourij,et al.  Multicentric Validation of Proteomic Biomarkers in Urine Specific for Diabetic Nephropathy , 2010, PloS one.

[54]  C. Isales,et al.  Glucose-dependent insulinotropic peptide: differential effects on hepatic artery vs. portal vein endothelial cells. , 2004, American journal of physiology. Endocrinology and metabolism.

[55]  P. Osmark,et al.  NFAT regulates the expression of AIF-1 and IRT-1: yin and yang splice variants of neointima formation and atherosclerosis. , 2012, Cardiovascular research.

[56]  C. Giachelli,et al.  The role of osteopontin in inflammatory processes , 2009, Journal of Cell Communication and Signaling.

[57]  M. Alam,et al.  Gastric inhibitory polypeptide (GIP) responses in type 2 diabetes using three different antibodies. , 1993, Annals of Saudi medicine.

[58]  A. Miyazaki,et al.  Effects of PKF275-055, a dipeptidyl peptidase-4 inhibitor, on the development of atherosclerotic lesions in apolipoprotein E-null mice. , 2012, Metabolism: clinical and experimental.

[59]  H. Singer,et al.  The non-excitable smooth muscle: Calcium signaling and phenotypic switching during vascular disease , 2008, Pflügers Archiv - European Journal of Physiology.

[60]  G. Berglund,et al.  Design and feasibility , 1993 .

[61]  D. Dransfield,et al.  Glucose-dependent insulinotropic peptide signaling pathways in endothelial cells , 2000, Peptides.

[62]  K. Eriksson,et al.  Long‐term outcome of the Malmö Preventive Project: mortality and cardiovascular morbidity , 2000, Journal of internal medicine.

[63]  A. Gottsäter,et al.  Suboptimal treatment of risk factor for atherosclerosis in critical limb ischemia. , 2005, International angiology : a journal of the International Union of Angiology.

[64]  J. Bonnet,et al.  Autocrine expression of osteopontin contributes to PDGF-mediated arterial smooth muscle cell migration. , 2007, Cardiovascular research.

[65]  M. Pfeffer,et al.  Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme , 2003, The Lancet.

[66]  J. Holst,et al.  Incretin secretion in relation to meal size and body weight in healthy subjects and people with type 1 and type 2 diabetes mellitus. , 2003, The Journal of clinical endocrinology and metabolism.

[67]  J. Holst,et al.  Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes. , 2006, The Journal of clinical endocrinology and metabolism.

[68]  Limei Liu,et al.  Protective Effects of Glucagon-like Peptide 1 on Endothelial Function in Hypertension , 2015, Journal of cardiovascular pharmacology.

[69]  J. Habener,et al.  Printed in U.S.A. Copyright © 2000 by The Endocrine Society Glucose-Dependent Insulinotropic Polypeptide Confers Early Phase Insulin Release to Oral Glucose in Rats: Demonstration by a Receptor Antagonist* , 2000 .

[70]  Li Yang,et al.  Endothelin-1 regulates rat bone sialoprotein gene transcription. , 2010, Journal of oral science.

[71]  Craig Wilson,et al.  Alogliptin after acute coronary syndrome in patients with type 2 diabetes. , 2013, The New England journal of medicine.

[72]  C. Alpers,et al.  Osteopontin is elevated during neointima formation in rat arteries and is a novel component of human atherosclerotic plaques. , 1993, The Journal of clinical investigation.

[73]  J. Molkentin,et al.  Novel blocker of NFAT activation inhibits IL-6 production in human myometrial arteries and reduces vascular smooth muscle cell proliferation. , 2007, American journal of physiology. Cell physiology.

[74]  T. Masaki.  Historical review: Endothelin. , 2004, Trends in pharmacological sciences.

[75]  L. Groop,et al.  Link Between GIP and Osteopontin in Adipose Tissue and Insulin Resistance , 2013, Diabetes.

[76]  S. Chakrabarti,et al.  Alteration of Endothelins: A Common Pathogenetic Mechanism in Chronic Diabetic Complications , 2002, International journal of experimental diabetes research.

[77]  Joshua J. Neumiller.  Clinical pharmacology of incretin therapies for type 2 diabetes mellitus: implications for treatment. , 2011, Clinical therapeutics.

[78]  Reiko Ohmori,et al.  Plasma osteopontin levels are associated with the presence and extent of coronary artery disease. , 2003, Atherosclerosis.

[79]  C. Mcintosh,et al.  Pleiotropic actions of the incretin hormones. , 2010, Vitamins and hormones.

[80]  J. Holst,et al.  Secretion of Glucose-Dependent Insulinotropic Polypeptide in Patients With Type 2 Diabetes , 2013, Diabetes Care.

[81]  L. Groop,et al.  Regulation of the pro-inflammatory cytokine osteopontin by GIP in adipocytes--a role for the transcription factor NFAT and phosphodiesterase 3B. , 2012, Biochemical and biophysical research communications.

[82]  A. Bonev,et al.  Opposing Actions of Inositol 1,4,5-Trisphosphate and Ryanodine Receptors on Nuclear Factor of Activated T-cells Regulation in Smooth Muscle* , 2002, The Journal of Biological Chemistry.

[83]  M. Monami,et al.  Dipeptidyl peptidase‐4 inhibitors and cardiovascular risk: a meta‐analysis of randomized clinical trials , 2013, Diabetes, obesity & metabolism.

[84]  A. Gottsäter,et al.  Inflammatory mediators are associated with 1-year mortality in critical limb ischemia. , 2005, Journal of vascular surgery.

[85]  D. Drucker,et al.  Cardiovascular biology of the incretin system. , 2012, Endocrine reviews.

[86]  C. Mcintosh,et al.  GIP increases human adipocyte LPL expression through CREB and TORC2-mediated trans-activation of the LPL gene , 2010, Journal of Lipid Research.

[87]  J. Holst,et al.  Normal secretion and action of the gut incretin hormones glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide in young men with low birth weight. , 2005, The Journal of clinical endocrinology and metabolism.

[88]  Barbara Burwinkel,et al.  Association analyses of GIP and GIPR polymorphisms with traits of the metabolic syndrome. , 2007, Molecular nutrition & food research.

[89]  W. Hsueh,et al.  Angiotensin II-accelerated atherosclerosis and aneurysm formation is attenuated in osteopontin-deficient mice. , 2003, The Journal of clinical investigation.

[90]  L. Groop,et al.  A family history of diabetes is associated with reduced physical fitness in the Prevalence, Prediction and Prevention of Diabetes (PPP)–Botnia study , 2010, Diabetologia.

[91]  Johanna Kuusisto,et al.  Changes in Insulin Sensitivity and Insulin Release in Relation to Glycemia and Glucose Tolerance in 6,414 Finnish Men , 2009, Diabetes.

[92]  JonathanGolledge,et al.  Osteoprotegerin and Osteopontin Are Expressed at High Concentrations Within Symptomatic Carotid Atherosclerosis , 2004 .

[93]  M. Laakso,et al.  Association between liver insulin resistance and cardiovascular risk factors , 2012, Journal of internal medicine.

[94]  M. Farrall,et al.  European rational approach for the genetics of diabetic complications--EURAGEDIC: patient populations and strategy. , 2007, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.